BackFidelity Select Portfolios - Medical Technology and Devices Portfolio Overview

Fidelity Select Portfolios - Medical Technology and Devices Portfolio Current Cash

Track Fidelity Select Portfolios - Medical Technology and Devices Portfolio's current cash ($45M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$44.62M

Peer trimmed avg / median

Loading

Fidelity Select Portfolios - Medical Technology and Devices Portfolio Current Cash History

Loading

Fidelity Select Portfolios - Medical Technology and Devices Portfolio vs. peers: Current Cash Comparison

Loading

Fidelity Select Portfolios - Medical Technology and Devices Portfolio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Fidelity Select Portfolios - Medical Technology and Devices Portfolio (FSMEX) FAQ

Fidelity Select Portfolios - Medical Technology and Devices Portfolio's current cash stands at $45M as of October 2023. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether Fidelity Select Portfolios - Medical Technology and Devices Portfolio's current cash is expanding or contracting. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Fidelity Select Portfolios - Medical Technology and Devices Portfolio's current cash evolved across reporting periods, while the comparison chart places FSMEX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.